The Mitochondrial Connection: How Diabetes and Chemotherapy Can Drive Peripheral Neuropathy

Peripheral neuropathy has two common causes that look nothing alike. Diabetes damages nerves over years of high blood sugar. Chemotherapy does it with a drug built to kill dividing cells.

Different routes, same destination: the mitochondria, the cell’s power plant. That isn’t news in functional medicine. What’s changed is that the evidence caught up. Here’s what it supports, and where it runs out.

Why Nerves Take the Hit

Peripheral nerves are among the hungriest cells you have, burning ATP constantly to hold their charge, fire signals, move cargo, and repair themselves. [1]

And they’re long. The cell body sits near your spine and ships everything down a fiber that can run several feet to your toes. The tip is last in line, where symptoms usually start. [2] When energy production drops, these cells feel it first. And in both conditions, the thing that falters is the same: the mitochondria.

• Diabetes overwhelms the electron transport chain inside the mitochondria, causing electrons to escape as superoxide. [3] That’s where the rest of the damage starts. It sets off the chain reactions that do the actual harm. Which is why getting your blood sugar number down stops new damage without undoing what’s already been done.
• Chemotherapy isn’t one mechanism either. Six drug groups can cause chemotherapy-induced peripheral neuropathy (CIPN), and they don’t all work the same way. [4] Taxanes drive up oxidative stress and trigger calcium release. Mitochondria normally buffer calcium in sensory neurons, so losing that leaves them abnormally excitable. Platinum drugs attack mitochondrial DNA, blocking it from being copied. The cell then has a harder time replacing its energy machinery as it wears out. [5] That’s part of why the damage keeps progressing after the last infusion.

Why the Damage Outlasts the Cause

In both diabetic and chemotherapy-induced neuropathy, fixing the cause doesn’t always fix the pain. The trigger can be gone, but the damage keeps running on its own.

The Damage Feeds Itself

Damaged mitochondria leak reactive oxygen species (ROS) faster than the body can clear them. Then it compounds.

ROS damages mitochondrial DNA and the proteins that make up the energy machinery. The damaged machinery leaks more ROS, which creates a feed-forward mechanism. [5]

The Neighbors Stop Helping

A sensory neuron doesn’t look after its own mitochondria. Satellite glial cells wrapped around it help deliver them through tiny tubes. Your nerve is being resupplied by the cells sitting right next to it.

That handoff breaks in two different ways. In diabetic peripheral neuropathy (DPN), the glial cells make fewer of the proteins that build these tubes, so fewer mitochondria make it through. After chemotherapy, the glial cells themselves get damaged, shutting down the supply line and leaving the nerve without the mitochondria it needs. [6]

The Structure Breaks Down

Mitochondria constantly merge and divide, and that balance is part of how they stay healthy. In diabetic neuropathy, high glucose tips that balance toward splitting, leaving mitochondria fragmented and fewer. [7]

The Nerve Can’t Clear or Replace Them

Two repair systems stall:

• Clearance: Mitophagy slows, so damaged mitochondria build up.
• Replacement: PGC-1α, which helps make new mitochondria, drops in diabetic nerve tissue. Lower levels are linked to worse neuropathy in animal studies. [8]

The nerve ends up with damaged mitochondria it can’t clear or replace.

Better Blood Sugar Doesn’t Fix Diabetic Neuropathy

Improving blood sugar is still one of the best things you can do for your nerves. The pain just doesn’t always improve when the numbers do.

In long-term follow-up of people with type 1 diabetes, earlier blood sugar control continued to affect nerve risk years later, even after HbA1c levels became similar. [9]

It’s called metabolic memory, but cells don’t remember. High blood sugar can leave the mitochondria stressed, slow the cleanup of damaged mitochondria, and disrupt the system that replaces them.

Much of this research is still preclinical. But it helps explain why getting blood sugar down, while essential, doesn’t always reverse what’s already happened.

How Energy Failure Becomes Neuropathic Pain

This is where the dorsal root ganglion comes in. It’s a cluster of sensory nerve cells sitting beside your spine, and it’s where the signal starts.

The Threshold Drops

Every sensory neuron has a firing threshold, the point at which it sends a signal. Two things can make these neurons fire too easily.

• Energy: Every time a nerve fires, sodium floods in and has to be pumped back out again. That pump runs on ATP. When energy production drops, it can’t keep up with demand, which is why these nerves tire out. Combined with weakened sodium currents, that may be enough to stop the signal getting through at all. [10]
• Oxidation: ROS can trip pain-sensing channels like TRPA1 directly, sparking spontaneous pain and cranking up sensitivity. These ROS build up inside the sensory ganglia, keeping those pain pathways stuck on high alert. [11]

Push this far enough and the neuron fires without a real stimulus. Your brain receives those signals as pain, even though nothing is touching you.

The Spinal Cord Filters Less

The misfiring starts at the nerve. It gets worse further up, in the spinal cord, for a reason that has less to do with energy and more to do with lost braking.

In the spinal cord’s dorsal horn, GABA acts as a brake on how much pain gets passed along. That brake can weaken.

• Chemotherapy ramps up a transporter that vacuums GABA out of the synapse too fast, causing your spinal cord’s natural braking system to fade out. [12]
• In diabetes, the spinal cord’s recycling pathway goes into overdrive and breaks down GABA receptors, wiping out your primary pain brakes. Blocking that destruction pathway restores the receptors and drives pain thresholds back up. [13]

What This Changes About How We Think About Neuropathy

We tend to treat neuropathy as a pain problem. Fair enough. Pain is what brings people in.

But pain medications target the signal, not the nerve generating it. And when it comes to CIPN, the toolkit is surprisingly bare: ASCO guidelines list duloxetine as the only drug with enough evidence to even recommend, and even then, its benefits are limited. [14]

Targeting Mitochondrial and Redox Health

Alpha-Lipoic Acid (ALA)

For oxidative stress related damage, ALA is the direct counter. It mops up reactive molecules and improves blood flow to nerves. A review of nine trials found that three weeks of IV ALA reduced burning, numbness, and prickling. [15]

But long-term structural repair of deeper lower-limb damage requires time, and oral ALA stood alone as the only route supported by high-quality evidence for that long-term recovery.

The difference comes down to timing. IV provides the initial symptom breakthrough, while long-term oral therapy builds the foundation for lasting nerve health. [15]

A smaller paclitaxel trial backed this up, showing that daily ALA improved neuropathy scores while driving down markers of oxidative stress. [16]

Going After the Source

Most antioxidants clean up ROS after they’re already made. But what if we shut down the factory generating them?

One candidate is NOX2. In a nerve injury model, NOX2 stayed elevated in the dorsal root ganglion for two weeks. Blocking the enzyme directly dialed down both nerve hyperexcitability and pain behaviors. [17]

It’s still preclinical, so this isn’t a treatment recommendation. But it gives us a new target to watch.

NAD+ Therapy

If the problem is failing energy and stalled repair, NAD+ is what both run on. Your mitochondria need NAD+ to make energy. It also supports enzymes involved in mitochondrial repair and renewal, which makes it an interesting option.

The research is encouraging, but it’s still preclinical. NAD+ precursors improved established neuropathy, including sensation, nerve conduction, and nerve fiber growth. [18] In cisplatin neuropathy, nicotinamide riboside both prevented and treated nerve damage, without blunting chemotherapy’s ability to kill tumor cells. [19]

Ways to Raise NAD+

• IV infusions: NAD+ goes straight into the bloodstream, bypassing digestion. It has to be given slowly because pushing it too fast can cause nausea, flushing, cramping, and headache.
• Oral precursors: Capsules of NR (nicotinamide riboside) taken daily. The most convenient option, and the one people are most likely to stick with. It raises NAD+ gradually rather than in a spike.
• Food: Your body builds NAD+ from vitamin B3 and tryptophan, which you get from foods like liver, salmon, tuna, mushrooms, and asparagus.
• Metabolic Shift: Burning ketones instead of glucose also consumes less NAD+, leaving more available.

Where This Leaves Us

Neuropathy is more than nerve damage to be managed. The evidence points to a metabolic problem, and that changes how we think about treatment.

That doesn’t mean we can reverse it. Some approaches relieve symptoms. Others help slow the damage. Managing the pain is only part of the job. Biology has been telling us that for years.

FAQs